Bank of New York Mellon Corp Decreases Stock Position in Zoetis Inc. $ZTS

Bank of New York Mellon Corp cut its holdings in Zoetis Inc. (NYSE:ZTS) by 9.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,899,720 shares of the company’s stock after selling 405,721 shares during the quarter. Bank of New York Mellon Corp’s holdings in Zoetis were worth $460,986,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Global Wealth Strategies & Associates bought a new stake in Zoetis in the 4th quarter worth about $25,000. Prosperity Bancshares Inc bought a new position in Zoetis during the 4th quarter valued at about $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis during the 4th quarter valued at about $30,000. Root Financial Partners LLC boosted its holdings in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. Finally, KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the third quarter valued at approximately $31,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis announced the acquisition of VitalRADS, which should deepen its diagnostics business and broaden its cloud-based, AI-assisted veterinary workflow tools. Zoetis Gains as VitalRADS Deal Boosts Diagnostics Narrative
• Positive Sentiment: Zoetis launched Lenivia in Canada and the EU, giving the company a new international treatment option for canine osteoarthritis pain and potentially supporting sales growth. Zoetis Launches Lenivia in Canada and the European Union
• Neutral Sentiment: Several law firms issued reminders about an upcoming July 27 lead-plaintiff deadline in the pending securities class action, keeping legal uncertainty in focus for investors. Zoetis Inc. Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class-action headlines highlight allegations of securities fraud tied to the period from January 2025 through May 2026, which could weigh on sentiment until the case is resolved. Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act

Insider Buying and Selling

In other news, Director Michael B. Mccallister acquired 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Morgan Stanley restated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research note on Friday, May 15th. TD Cowen cut their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Finally, UBS Group reduced their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $120.83.

Zoetis Trading Up 3.3%

NYSE:ZTS opened at $77.02 on Friday. The business has a fifty day moving average price of $77.46 and a 200-day moving average price of $106.24. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The firm has a market capitalization of $32.29 billion, a price-to-earnings ratio of 12.77, a price-to-earnings-growth ratio of 1.16 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the previous year, the firm earned $1.48 earnings per share. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.